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RESUMO
Introdução: Desde os anos 60 que o Citomegalovírus tem sido estudado pelo potencial papel no desenvolvimento de cancro do colo 
do útero. Após várias décadas de estudos e relatos da presença de DNA viral em amostras cervico-vaginais, ainda permanecem dúvi-
das sobre qual a prevalência do Citomegalovírus no cólo do útero e se este pode ser um cofator da carcinogénese.
Métodos: Nesta Revisão Sistemática pretendemos descrever a prevalência de Citomegalovírus em amostras cervicais, revendo todos 
os estudos publicados entre 1980 e 2011 que descrevem a infecção por Citomegalovírus em amostras cervicais e o desenvolvimento 
de lesões/carcinoma invasor. As frequências da infecção por Citomegalovírus foram calculadas de acordo com a região no mundo.
Resultados: Este estudo revelou que a frequência bruta da infecção por Citomegalovírus no cólo do útero foi de 18,9% em todas as 
amostras e 36,5% em mulheres HPV positivas. A infecção por Citomegalovírus está presente em todas as diferentes lesões: 17,4% 
em normais/cervicite, 28,0% em LSIL, 19,7% em HSIL e 44,4% em CIS/ICC. A frequência global variou de 1,58% a 61,0%, com uma 
maior incidência em países menos desenvolvidos.
Conclusão: Neste estudo, verificou-se uma elevada frequência de casos positivos para Citomegalovírus em todos os tipos de 
amostras cervico-vaginais, com maior incidência em mulheres infectadas por HPV e em casos de cancro. Assim, são necessários 
mais estudos para esclarecer se a infecção por Citomegalovírus é uma infecção oportunista ou se contribui para a imunossupressão 
favorecendo a carcinogénese associada ao HPV.
Palavras-chave: Citomegalovírus; Infecções por Citomegalovírus  Neoplasias do Colo do Útero.
ABSTRACT
Background: Since early 60’s that Cytomegalovirus was studied for its possible role in cervical cancer development. Despite several 
decades of studies and the description of CMV DNA in cervical samples, it is still doubtful what is the prevalence of Cytomegalovirus in 
cervix and if CMV can act as a co-factor in cervical carcinogenesis. 
Methods: In this Systematic Review we intend to summarize the frequency of Cytomegalovirus in cervical samples by revising all 
published studies between 1980 and 2011 regarding the detection of Cytomegalovirus in cervical samples and the development of le-
sions/invasive cervical cancer. Crude and adjusted frequencies of Cytomegalovirus infection were calculated according to country and 
world region.
Results: This study revealed that the worldwide crude frequency of Cytomegalovirus infection in the cervix was 18.9% in all cervical 
samples and 36.5% in HPV positive women. Cytomegalovirus infection was present in all different types of lesions: 17.4% in normal/
cervicitis, 28.0% in LSIL, 19.7% in HSIL and 44.4% in CIS/ICC. The overall rate of Cytomegalovirus infection varied from 1.58% to 
61.0% with an increased incidence in less developed countries. 
Conclusion: In this study we described a high frequency of positive Cytomegalovirus cases in all types of cervical samples, with 
increased incidence in both HPV-infected women and CIS/ICC cases. Hence, despite results showed that Cytomegalovirus shedding 
in cervical samples is frequent more studies should be performed to clarify if Cytomegalovirus infection is an opportunistic infection in 
HPV-infected cases, or if it contributes for cervical immunosuppression that will favor HPV-associated carcinogenesis. 
Keywords:  Cytomegalovirus; Cytomegalovirus Infections; Uterine Cervical Neoplasms.
INTRODUCTION
 Cervical cancer is the third most common female cancer 
worldwide. Although there have been advances in detection 
and treatment, cervical cancer is still a major health issue, 
especially in developing countries.1 In developed countries 
several enhancements have been made in prevention and 
treatment leading to a decline of both incidence and mortal-
ity.2 Persistent infection by oncogenic types of HPV, such 
as HPV16, 18, 31, 45 and others, are considered the etio-
logical factor for cervical carcinoma development. Although 
HPV is not a sufficient factor for developing cervical cancer, 
several other co-factors were identified, such as: smoking, 
infection by other sexually transmitted diseases (STI) (Hu-
man Immunodeficiency Virus, Chlamydia trachomatis, Cy-
tomegalovirus, etc.), long term use of oral contraceptives, 
intrauterine device use, multiple full-term pregnancies, 
young age at full-term pregnancy and poverty.2-4
 Human Herpesviruses (HHVs) can induce cell transfor-
mation by production of oncogenic proteins or by interacting 
with cell replication, which are important steps for cancer 
development5 For many years, CMV was one of the HHVs 
that was thought to have a role in the development of cervi-
cal lesions.6 CMV infects between 50 to 85% of the world-
wide population by early adulthood. It can be transmitted 
orally, sexually and parenterally.7 Although CMV is not cor-
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Figure 1 – Flowchart of application of inclusion/exclusion criteria.
related to human cancer some studies suggest that it may 
be specifically associated with some human malignancies.8 
CMV DNA has been found in cervico-vaginal secretions; 
however no correlation has been made between this virus 
and the development of cervical carcinoma.6,9-12
 The aim of this study was to perform a systematic re-
view of all published data regarding CMV infection in the 
cervix, to determine what is the relationship between CMV 
infection and the development of lesions/invasive cervical 
cancer.
METHODS
Articles search and Selection criteria.
 This systematic review was performed by searching 
Pubmed/Medline databases using the following query: 
(“Cytomegalovirus”[Mesh] OR “cytomegalovirus”[All Fields] 
OR “CMV”[All Fields] OR “Herpesvirus 5”[All Fields] OR “Hu-
man Herpesvirus 5”[All Fields] OR “HHV-5”[All Fields] OR 
“human cytomegalovirus”[All Fields] OR “HCMV”[All Fields] 
OR “citomegalovirus”[All Fields] OR “Cytomegalovirus 
Infections”[Mesh] OR “Cytomegalic”[All Fields]) AND (“uter-
ine cervical neoplasms”[Mesh] OR “cervical intraepithelial 
neoplasia”[Mesh] OR “uterine cervical dysplasia”[Mesh] OR 
“uterine cervical diseases”[Mesh] OR “cervix infection”[All 
Fields] OR “cervix uteri”[MeSH] OR “cervix uteri”[All Fields] 
OR (“cervix”[All Fields] AND “uteri”[All Fields]) OR “cervix”[All 
Fields] OR “Uterus”[Mesh] OR “uterine”[All Fields]). 
 To be included in the study articles should clearly in-
clude data from CMV detection in cervical samples. Arti-
cle search was restricted to data published after 1980 and 
included all articles available in English, French, Spanish, 
and Portuguese. We have also considered the references 
list of selected articles to identify additional studies. 
Data extraction
 Included studies were revised by the authors, in order to 
extract the necessary information to perform the analysis: 
design of study (case-control and case study), source of 
sample (cervical swabs or smears and biopsies), popula-
tion, geographical location (region and continent), type of 
cervical lesions, presence or absence of Human Papilloma-
virus infection, CMV diagnostic methodology (Polymerase 
Chain Reaction, Nested, Real-time PCR, in situ Hybridiza-




 The literature searches yielded a total of 376 articles 
from which we have obtained 26 published articles3,11-35 to 
include in the systematic review (Fig. 1). Studies were ex-
cluded considering the following criteria: 1) articles older 
than 1980 (n = 30); 2) language, such as Russian, Polish, 
Chinese, Japanese or Italian (n = 21); 3) study performed 
in male population (n = 3); 4) other types of articles such as 
case reports (n = 25), reviews (n = 57) and letters (n = 7); 
5) other types of samples than cervico-vaginal (n = 60); 6) 
other types of studies, such as in vitro studies (n = 24) and 
in vivo studies (n = 20); and 7) studies not related to the aim 
of this study (n = 66). Some of the 63 articles included were 
not available after request to authors (n = 37).
 The 26 studies were performed in 17 different countries: 
8 from Asia (China, India, Japan, Thailand and Turkey), 12 
from Europe (Croatia, Denmark, Finland, Germany, Greece, 
Italy, Netherland and Poland), 2 from Africa (Kenya), 1 from 
Oceania (Australia) and 6 from North-America (Canada, 
USA). Studies were very different in the number of cases 
included, ranging from 17 to 1685 cases (mean 239 ± 337; 
median 143). The total number of cases was 6936 with the 
great majority of studies to be was conducted in Europe 
with a total of 1825 individuals, followed by Asia with 1490 
individuals, North-America with 3118 individuals, Africa with 
328 individuals and Oceania with 175 individuals (Table 1).
 From the final 26 studies it was possible to identify a 
total of 29 individual populations on which CMV infection 
was characterized in cervical samples with different types 
of lesions. These individual populations include one group 
of women with with endometriosis, three from Human Im-
munodeficiency Virus (HIV) positive women, four from 
pregnant women, two from non-pregnant, two from women 
attending a STD clinic and seventeen regarding general 
population. The type of sample used to test CMV was also 
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different among the different populations: 16 with cervical 
swabs, 10 with cervical smears and 3 with biopsies.
 Regarding the type of cervical lesions we found: seven 
studies with normal/cervicitis cases from Europe (n = 4), 
Asia (n = 2) and America (n = 1); six studies with low-grade 
squamous intraepithelial lesions (LSIL) from Europe (n = 5) 
and Asia (n = 1); nine studies with high-grade squamous 
intraepithelial lesions (HSIL) from Europe (n = 7) and Asia 
(n = 2); six studies with CIS/ICC from Europe (n = 3) and 
Asia (n = 3); and three studies with atypical squamous cells 
(ASC) from Europe. Moreover, considering the HPV infec-
tion status, we observed that only a minority of studies pro-
vided these data (n = 7), including a total of 535 cases, of 
which 302 individuals were from Asiatic countries and 233 
individuals from Europe (Table 1). 
 Finally, we observed that the most common methodol-
ogy for CMV diagnosis was Polymerase Chain Reaction 
(PCR) (n = 16), followed by Culture with indirect immuno-
fluorescence (n = 7), Real-time PCR (n = 3), In situ Hybridi-
zation (n = 2) and one Nested-PCR (n = 1).
Data Analysis
 Table 1 and 2 show the crude and adjusted frequency 
of CMV in different cervical lesions with pooled frequencies 
to be estimated by country and continent: crude rates were 
calculated by (∑CMV+cases/∑all cases) x 100; and adjusted rate 
was calculated as the average frequency of CMV positive 
cases. 
 The analysis of CMV infection status among all studies, 
revealed an overall crude frequency of 18.9% and adjusted 
frequency of 24.5% in cervical samples. Studies from Africa 
revealed the highest frequency, followed by Asia, Europe, 
North-America and Oceania (61.0%, 26.9%, 16.6%, 12.8% 
and 6.29%, respectively). Considering HPV infection, we 
observed that only studies from Europe and Asia showed 
data concerning HPV status, revealing an overall frequency 
of CMV infection of 36.4% in HPV positive women and ad-
justed frequency of 40.8%. Curiously, the crude frequency 
was significantly different from Europe to Asia (52.8% vs. 
23.8%, respectively), while adjusted frequency revealed 
similar data. Considering the different cervical lesions, our 
study revealed an overall crude CMV frequency of 27.0% 
in Europe, 10.2% in China and 11.3% in USA in normal/
cervicitis cases, with an overall global rate of 17.4%; in LSIL 
cases, CMV infection was present in 32.6% for Europe and 
16.1% for China, with a global rate of 28.0%; in HSIL, data 
sowed an overall rate of 23.9% for Europe and 10.0% for 
China with a global rate of 19.7%; finally, in CIS/ICC cases, 
the analysis revealed a CMV frequency of 48.6% in Europe 
and 41.2% for Asia, with a global rate of 44.4%.
DISCUSSION
 Cytomegalovirus is recognized as one of the most fre-
quent viruses to infect the genital tract. Nevertheless, there 
is no study that clearly characterizes CMV infection in cervi-
cal epithelium.3,32 After primary infection CMV is thought to 
develop a persistent infection in the genital tract with chroni-
cle viral shedding in the cervix.36 Moreover, several stud-
ies revealed that CMV can induce transformation of cells in 
vitro which could lead to cancer development. Despite the 
evidences and even considering that CMV could be found 
in biopsies of cervical carcinomas, CMV has not proved to 
be the causative agents of ICC. Nevertheless, CMV infec-
tion has been alleged to increase the risk of developing cer-
vical cancer and although there are studies that report the 
presence of CMV in the cervix, only few studies refer the 
use of cervico-vaginal swabs or scrapes.9,32,36
 An association between CMV infection and the devel-
opment of cervical lesions/cancer is still the main question 
nowadays. In hospitalized patients the diagnosis of CMV 
infection is mainly performed by antigenemia or polymer-
ase chain reaction (PCR). Antigenemia is frequently applied 
to follow-up patients and is the gold-standard technique in 
CMV detection, although, PCR is being described as more 
reliable and with higher sensitivity associated. Despite CMV 
detection is more often performed by serological characteri-
zation with about 50-85% of positive cases.7 Several stud-
ies indicate that CMV DNA may be found in cervico-vaginal 
samples even when undetectable in the blood.6,9,11,12 In fact, 
data points to a variation between only 2 to 66% of CMV 
positivity in cervico-vaginal samples and PCR or Real-time 
PCR are being suggested as the best approach for CMV 
detection.3,32,37-39 
 In this study, we have performed a systematic review 
of literature considering CMV and cervical lesions/cancer. 
Throughout acquisition of articles there were some major 
concerns: of the 376 articles obtained by the query, only 63 
met the selection criteria. Of these 63 articles, 37 were not 
available mainly because articles were not accessible for 
free or institution subscription or even because authors did 
not reply to emails; another concern was the types of sam-
ples leading to exclusion of 60 articles because prevalence 
characterization of CMV infection was performed by serol-
ogy/antigenemia in blood or serum samples.
 Of all articles published we identified a total of 26 articles 
corresponding to 29 individual populations where CMV was 
analysed in cervico-vaginal samples. Considering these 
studies distribution of CMV infection by region varies signifi-
cantly. The overall CMV infection frequency was of 18.9%: 
Africa showed the higher crude frequency (61.0%), followed 
by Asia with 26.9%, Europe with 16.6%, North-America with 
12.8% and finally Oceania with 6.29%. Considering that 
there is a significant variation of number of individuals in 
the different we have calculated an adjusted frequency for 
CMV infection (24.5% worldwide): Africa remains the leader 
with the higher adjusted frequency (79.4%), followed by 
Asia (31.1%), Europe (16.7%) and North-America (16.1%). 
This variation in CMV infection frequency may be either 
correlated with specific population distribution or it may be 
explicated by the significant variations in the numbers of 
individuals analysed in each study. Nevertheless, these 
data show that CMV infection is significantly more prevalent 
amongst developing countries than developed. 
 CMV infection might not be the cause of cervical cancer 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































development, but several authors state that it might act as 
an inductor in HPV carcinogenesis. In fact, there are studies 
that refer that persistent infection by CMV leads to a higher 
predisposition to acquire HPV infection.23 In our study, the 
overall crude CMV frequency amongst HPV positive wom-
en was of 36.5% and the adjusted frequency of 40.8%. This 
analysis was only possible for 7 populations, 3 from Europe 
and 4 from Asia, yet, this analysis revealed that co-infection 
of CMV with HPV was more prevalent in Europe than Asia 
(52.8% vs. 23.8%, respectively). This data might constitute 
a bias in the overall analysis of CMV association with HPV 
infection and the possible explanations for this fact are: 
number of individuals, age distribution or type of lesions.
CONCLUSION
 Since our study discriminated the data of CMV frequen-
cy according to the different types of cervical lesions, we 
have observed that CMV is frequently found in the differ-
ent lesions. Moreover, we observed that the frequency was 
lower in Normal/Cervicitis cases (17.4%) and that it is more 
prevalent in CIS/ICC cases (44.4%). The frequency of CMV 
infection did not show an increasing tendency as cervical 
lesions progress, although, the higher frequency amongst 
CIS/ICC cases may be correlated with a reactivation of 
CMV infection.
 Overall, this systematic review revealed that CMV shed-
ding in cervical samples is frequent and that it may be cor-
related with cervical cancer development, mainly after HPV-
infection. Despite it was not possible to show a real role 
of CMV in the development of cervical cancer, the data of 
viral shedding in normal samples suggest that more stud-
ies should be performed to elucidate if CMV infection is an 
opportunistic infection in HPV-infected cases, or if it contrib-
utes for cervical immunosuppression that will favor HPV-
associated carcinogenesis.
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